Sanofi-A Ventis Deutschland Gmbh

Aventis Pharmaceuticals Inc.

Mcmaster University

Hertzel Gerstein

Ralf Rosskamp

Thorsten Sadowski

Gregory Steinberg

Sibylle Hess

Bernward Schoelkens

Guillaume Pare

Salim Yusuf

Bernward Schölkens

Norbert Bender

Badrudin Rangoonwala

Gilles Dagenais

Sybille Hess

Matthew Mcqueen

The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.

Growth differentiation factor 15 as biomarker for metformin

This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.

Method for reducing cardiovascular morbidity and mortality in prediaetic patients and patients with type 2 diabetes

Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes

Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.

Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Growing community of inventors

Hamilton, Canada

Hertzel Gerstein